10647 related articles for article (PubMed ID: 12952296)
21. Production and characterization of tumor infiltrating lymphocyte clones derived from B16-F10 murine melanoma.
Maeda K; Lafreniere R; Jerry LM
J Invest Dermatol; 1991 Aug; 97(2):183-9. PubMed ID: 2071934
[TBL] [Abstract][Full Text] [Related]
22. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo.
Tahara H; Zeh HJ; Storkus WJ; Pappo I; Watkins SC; Gubler U; Wolf SF; Robbins PD; Lotze MT
Cancer Res; 1994 Jan; 54(1):182-9. PubMed ID: 7903204
[TBL] [Abstract][Full Text] [Related]
23. Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma.
Rhines LD; Sampath P; DiMeco F; Lawson HC; Tyler BM; Hanes J; Olivi A; Brem H
Neurosurgery; 2003 Apr; 52(4):872-9; discussion 879-80. PubMed ID: 12657184
[TBL] [Abstract][Full Text] [Related]
24. Treatment with allogeneic interleukin-2 secreting fibroblasts protects against the development of malignant brain tumors.
Glick RP; Lichtor T; Panchal R; Mahendra A; Cohen EP
J Neurooncol; 2003; 64(1-2):139-46. PubMed ID: 12952294
[TBL] [Abstract][Full Text] [Related]
25. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells.
Yu JS; Burwick JA; Dranoff G; Breakefield XO
Hum Gene Ther; 1997 Jun; 8(9):1065-72. PubMed ID: 9189764
[TBL] [Abstract][Full Text] [Related]
26. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
[TBL] [Abstract][Full Text] [Related]
27. Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats.
DiMeco F; Rhines LD; Hanes J; Tyler BM; Brat D; Torchiana E; Guarnieri M; Colombo MP; Pardoll DM; Finocchiaro G; Brem H; Olivi A
J Neurosurg; 2000 Mar; 92(3):419-27. PubMed ID: 10701528
[TBL] [Abstract][Full Text] [Related]
28. IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma.
Lucas ML; Heller R
DNA Cell Biol; 2003 Dec; 22(12):755-63. PubMed ID: 14683586
[TBL] [Abstract][Full Text] [Related]
29. Gene transfer of secreted-type modified interleukin-18 gene to B16F10 melanoma cells suppresses in vivo tumor growth through inhibition of tumor vessel formation.
Nagai H; Hara I; Horikawa T; Oka M; Kamidono S; Ichihashi M
J Invest Dermatol; 2002 Sep; 119(3):541-8. PubMed ID: 12230493
[TBL] [Abstract][Full Text] [Related]
30. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon.
Abdel-Wahab Z; Dar M; Osanto S; Fong T; Vervaert CE; Hester D; Jolly D; Seigler HF
Cancer Gene Ther; 1997; 4(1):33-41. PubMed ID: 9012449
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
32. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma.
Lucas ML; Heller L; Coppola D; Heller R
Mol Ther; 2002 Jun; 5(6):668-75. PubMed ID: 12027550
[TBL] [Abstract][Full Text] [Related]
33. Elimination of CD4(+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration.
Nagai H; Hara I; Horikawa T; Oka M; Kamidono S; Ichihashi M
J Invest Dermatol; 2000 Dec; 115(6):1059-64. PubMed ID: 11121142
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of hepatocellular carcinoma by transfecting interleukin-12 and interleukin-2 fusion gene intrasplenically, an experimental study].
Yang JH; Fan RF; Qian QJ; You TG; Xue HB; Su CQ; Cao HF; Wu MC
Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):740-3. PubMed ID: 12899748
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-6-type cytokines and their receptors for gene therapy of melanoma.
Mackiewicz A; Wiznerowicz M; Roeb E; Nowak J; Pawlowski T; Baumann H; Heinrich PC; Rose-John S
Ann N Y Acad Sci; 1995 Jul; 762():361-73; discussion 373-4. PubMed ID: 7668537
[TBL] [Abstract][Full Text] [Related]
36. In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors.
Ram Z; Walbridge S; Heiss JD; Culver KW; Blaese RM; Oldfield EH
J Neurosurg; 1994 Mar; 80(3):535-40. PubMed ID: 8113867
[TBL] [Abstract][Full Text] [Related]
37. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
[TBL] [Abstract][Full Text] [Related]
38. Genetic immunotherapy by intrapleural, intraperitoneal and subcutaneous injection of IL-2 gene-modified Lewis lung carcinoma cells.
Heike Y; Takahashi M; Ohira T; Naruse I; Hama S; Ohe Y; Kasai T; Fukumoto H; Olsen KJ; Podack EE; Saijo N
Int J Cancer; 1997 Dec; 73(6):844-9. PubMed ID: 9399664
[TBL] [Abstract][Full Text] [Related]
39. Combined immunotherapy and antiangiogenic therapy of cancer with microencapsulated cells.
Cirone P; Bourgeois JM; Shen F; Chang PL
Hum Gene Ther; 2004 Oct; 15(10):945-59. PubMed ID: 15585110
[TBL] [Abstract][Full Text] [Related]
40. Anti-tumor activity of interleukin-2-producing tumor cells and recombinant interleukin 12 against mouse glioma cells located in the central nervous system.
Kikuchi T; Joki T; Saitoh S; Hata Y; Abe T; Kato N; Kobayashi A; Miyazaki T; Ohno T
Int J Cancer; 1999 Jan; 80(3):425-30. PubMed ID: 9935185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
